Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 141.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,520 shares of the company’s stock after purchasing an additional 10,843 shares during the period. BNP Paribas Financial Markets’ holdings in Pediatrix Medical Group were worth $215,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group in the second quarter worth $33,000. Quest Partners LLC increased its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group in the 2nd quarter worth about $72,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

MD stock opened at $14.46 on Tuesday. The company has a market capitalization of $1.24 billion, a P/E ratio of -4.73, a PEG ratio of 2.00 and a beta of 1.57. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a 50-day simple moving average of $14.02 and a 200 day simple moving average of $10.83. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the business earned $0.29 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. Sell-side analysts predict that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MD has been the topic of several research reports. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. UBS Group upped their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Truist Financial lifted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $16.42.

Insider Buying and Selling

In related news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. The trade was a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.